Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

NCT01767493 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: [18F]Florbetapir PET imaging

Sponsor

Institute for Neurodegenerative Disorders

Collaborators

[object Object]